Literature DB >> 29113977

FDA Approves Second CAR T-cell Therapy.

.   

Abstract

The FDA approved the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel, making it the second such treatment for blood cancers in the United States. The therapy is indicated for adults with certain non-Hodgkin lymphomas who have tried at least two other treatments. ©2018 American Association for Cancer Research.

Entities:  

Year:  2017        PMID： 29113977     DOI： 10.1158/2159-8290.CD-NB2017-155

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  34 in total

1.  Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra.

Authors:  Shashidhar S Jatiani; Adolfo Aleman; Deepu Madduri; Ajai Chari; Hearn Jay Cho; Shambavi Richard; Joshua Richter; Joshua Brody; Sundar Jagannath; Samir Parekh
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-11

Review 2.  Enabling Technologies for Personalized and Precision Medicine.

Authors:  Dean Ho; Stephen R Quake; Edward R B McCabe; Wee Joo Chng; Edward K Chow; Xianting Ding; Bruce D Gelb; Geoffrey S Ginsburg; Jason Hassenstab; Chih-Ming Ho; William C Mobley; Garry P Nolan; Steven T Rosen; Patrick Tan; Yun Yen; Ali Zarrinpar
Journal:  Trends Biotechnol       Date:  2020-01-21       Impact factor: 19.536

Review 3.  The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy.

Authors:  Jessica B Foster; David M Barrett; Katalin Karikó
Journal:  Mol Ther       Date:  2019-02-02       Impact factor: 11.454

4.  Synthetic biology: Reframing cell therapy for cancer.

Authors:  Taylor B Dolberg; Patrick S Donahue; Joshua N Leonard
Journal:  Nat Chem Biol       Date:  2018-02-14       Impact factor: 15.040

Review 5.  The Landscape of Early Clinical Gene Therapies outside of Oncology.

Authors:  Laure Rittié; Takis Athanasopoulos; Miguel Calero-Garcia; Marie L Davies; David J Dow; Steven J Howe; Alastair Morrison; Ida Ricciardelli; Aurore Saudemont; Laurent Jespers; Timothy M Clay
Journal:  Mol Ther       Date:  2019-09-06       Impact factor: 11.454

Review 6.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

Review 7.  The Potential of CAR T Cell Therapy in Pancreatic Cancer.

Authors:  Mehmet Akce; Mohammad Y Zaidi; Edmund K Waller; Bassel F El-Rayes; Gregory B Lesinski
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

Review 8.  Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.

Authors:  Zhenguang Wang; Weidong Han
Journal:  Biomark Res       Date:  2018-01-22

Review 9.  Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches.

Authors:  Stefania Mantovani; Barbara Oliviero; Stefania Varchetta; Dalila Mele; Mario U Mondelli
Journal:  Cancers (Basel)       Date:  2020-04-09       Impact factor: 6.639

10.  Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory.

Authors:  Sophie Viaud; Jennifer S Y Ma; Ian R Hardy; Eric N Hampton; Brent Benish; Lance Sherwood; Vanessa Nunez; Christopher J Ackerman; Elvira Khialeeva; Meredith Weglarz; Sung Chang Lee; Ashley K Woods; Travis S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.